Hellmann, M.D., Chaft, J.E., William, W.N., Rusch, V., Pisters, K.M.W., Kalhor, N., et al. (2014) Pathological Response after Neoadjuvant Chemotherapy in Resectable Non-Small-Cell Lung Cancers: Proposal for the Use of Major Pathological Response as a Surrogate Endpoint. The Lancet Oncology, 15, e42-e50.
https://doi.org/10.1016/s1470-2045(13)70334-6

has been cited by the following article:

• TITLE: Current Research on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer

  AUTHORS: Lingzi Zheng, Ling Hu

  KEYWORDS: Non-Small Cell Lung Cancer, Perioperative, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.15 No.12, December 16, 2024

  ABSTRACT: For patients with lung cancer, there is yet to be an ideal clinical treatment, with surgical resection still being the preferred treatment choice. Compared to the clinical efficacy in patients with advanced non-small cell lung cancer (NSCLC), the recurrence rate remains high for early-stage resectable disease. In recent years, immune checkpoint inhibitors and targeted therapies have shown promise as two clinical treatment approaches. Many clinical studies are evaluating perioperative immunotherapy or targeted therapy, and recent trials such as CheckMate 816, CheckMate 77T, and bispecific nanoparticle BCGN introduce new concepts while demonstrating the clinical potential of these approaches. This review addresses recent and ongoing trials of neoadjuvant and adjuvant systemic therapies for NSCLC, and potential developments in this area in the near future.